Mucinase StcE 是 M66 家族的锌金属蛋白酶,可由肠出血性大肠杆菌通过 Ⅱ 型通用分泌途径分泌,能够特异性识别并切割含 α-O-聚糖的黏蛋白型糖蛋白(如 MUC2、Mucin 7、Glycoprotein 340、CD45、CD43、C1 Esterase Inhibitor (MS-C54176) 等)中的 'T*XT' 基序,并通过降解黏液层降低其黏度、抑制补体级联激活并将补体调节因子定位于细胞膜,从而协助细菌穿透黏膜屏障、黏附宿主细胞并逃避免疫清除,因此可作为黏蛋白特异性蛋白水解工具用于结肠、食管及唾液腺来源的黏液性癌的研究。
Mucinase StcE
产品编号: MS-J56765
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
100μg
询价
3-5 天

产品描述

Mucinase StcE 是 M66 家族的锌金属蛋白酶,可由肠出血性大肠杆菌通过 Ⅱ 型通用分泌途径分泌,能够特异性识别并切割含 α-O-聚糖的黏蛋白型糖蛋白(如 MUC2、Mucin 7、Glycoprotein 340、CD45、CD43、C1 Esterase Inhibitor (MS-C54176) 等)中的 'T*XT' 基序,并通过降解黏液层降低其黏度、抑制补体级联激活并将补体调节因子定位于细胞膜,从而协助细菌穿透黏膜屏障、黏附宿主细胞并逃避免疫清除,因此可作为黏蛋白特异性蛋白水解工具用于结肠、食管及唾液腺来源的黏液性癌的研究。

生物实验数据

生物活性 Mucinase StcE is a zinc metalloprotease of the M66 family that is secreted by enterohaemorrhagic Escherichia coli via the type II general secretion pathway, specifically recognizes and cleaves the 'T*XT' motif in α-O-glycan-containing mucin-type glycoproteins (such as MUC2, Mucin 7, Glycoprotein 340, CD45, CD43, C1 Esterase Inhibitor (MS-C54176), etc.), and assists bacteria in penetrating the mucosal barrier, adhering to host cells, and evading immune clearance by degrading the mucus layer to reduce its viscosity, inhibiting complement cascade activation, and localizing complement regulators to the cell membrane, thus serving as a mucin-specific proteolytic tool for research on mucinous carcinomas of colonic, esophageal, and salivary gland origin.
体外研究
(In Vitro)

Mucinase StcE (0.5-1 mg/mL) 在溶液中以单体形式存在,并且会与其底物 C1 Esterase Inhibitor (MS-C54176) 形成 1:1 的复合物。
Mucinase StcE (过夜; 37 °C) 可进行组织酶解,通过 MALDI-MSI 实现黏液癌组织中不同 MUC2 糖型和肿瘤特异性 O-糖肽的空间可视化。

体内研究
(In Vivo)

Mucinase StcE (0.1 μg/μL, 0.05 mg/mL; 过夜 (13-23 hour); 37°C) 可在人结直肠黏液腺癌样本中揭示经 Tn 和 T 抗原修饰的 MUC2 糖型的肿瘤特异性空间分离。
Mucinase StcE (0.1 μg/μL, 0.05 mg/mL; 过夜 (13-23 hour); 37°C) 可实现人涎腺黏液癌标本中 T 抗原主导的多功能蛋白聚糖糖型的空间定位与糖蛋白质组学鉴定。

Animal Model: archival formalin-fixed, paraffin-embedded tissue specimens (mucinous carcinoma patients)
Dosage: 0.1 µg/µL (sprayer-applied); 0.05 mg/mL (pipette-applied to tumor regions)
Administration: on-slide; overnight (13-23 hour) incubation at 37°C (for 0.05 mg/mL dose); one set of 15 passes (for 0.1 µg/µL dose)
Result: Enabled spatial mapping of MUC2 O-glycopeptides via MALDI-MSI, revealing distinct distribution patterns: Tn-only MUC2 glycopeptides clustered in specific tumor regions adjacent to fibrotic or non-mucinous malignant tissue, while glycoforms with both T and Tn antigens were diffusely distributed across the mucinous tumor, and T-only glycoforms localized near the tumor edge adjacent to adipose tissue.
Yielded 91.2% sequence coverage over the two PTS domains of MUC2 via LC-MS, with most localized O-glycans being Tn or T antigens; low-abundance core 2 structures, mono- and di-O-acetylated sialic acid-containing glycans, and a putative O-acetylated GalNAc modification were also identified.
Restricted StcE-derived O-glycopeptides exclusively within tumor boundaries.\nRevealed via MALDI-MSI that Tn-only MUC2 glycopeptides concentrated at a single tumor site bordering non-mucinous adenocarcinoma tissue, while T antigen-containing glycoforms spread over a larger portion of the tumor region.
Confirmed 91.2% sequence coverage over MUC2's two PTS domains via LC-MS, with dominant Tn and T antigen modifications, plus low-abundance modified glycans including di-O-acetylated sialic acid and putative O-acetylated GalNAc.
Restricted StcE-derived O-glycopeptides to tumor boundaries.
Animal Model: archival formalin-fixed, paraffin-embedded tissue specimens (mucinous carcinoma patients)
Dosage: 0.1 µg/µL (sprayer-applied); 0.05 mg/mL (pipette-applied to tumor regions)
Administration: on-slide; overnight (13-23 hour) incubation at 37°C (for 0.05 mg/mL dose); one set of 15 passes (for 0.1 µg/µL dose)
Result: Detected StcE-generated glycopeptides diffusely distributed across the tumor, with some spillover into adjacent parotid tissue via MALDI-MSI.
Revealed via LC-MS that glycopeptide results were dominated by versican, with core 1 and core 2 structures (with and without sialylation) localized on versican glycopeptides; most were decorated exclusively with T antigens, with very few Tn antigen-modified species.
性状 液体
颜色 Colorless to light yellow

化学信息

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础